Biotech Values

[DewDiligence]

Blurb from ABT 2Q11 CC re drug-eluting-stent market:

http://seekingalpha.com/article/280539-abbott-laboratories-management-discusses-q2-2011-results-earnings-call-transcript

…the thing that people forget about is international sales and markets for our overall DES portfolio make up more than 60% of our total global sales now. So we continue to see better growth in emerging markets, and PCI volume obviously in those markets is growing mid-teens versus flattish here in the U.S.

ABT will pick up share in the DES market due to JNJ’s withdrawal from the market (#msg-64256077).